Search by Drug Name or NDC
NDC 64764-0800-28 Livtencity 200 mg/1 Details
Livtencity 200 mg/1
Livtencity is a ORAL TABLET, COATED in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Takeda Pharmaceuticals America, Inc.. The primary component is MARIBAVIR.
Product Information
| NDC | 64764-0800 |
|---|---|
| Product ID | 64764-800_b15552d2-7462-4043-ab27-1e53128fcc93 |
| Associated GPIs | 12200050000320 |
| GCN Sequence Number | 082853 |
| GCN Sequence Number Description | maribavir TABLET 200 MG ORAL |
| HIC3 | W5A |
| HIC3 Description | ANTIVIRALS, GENERAL |
| GCN | 51574 |
| HICL Sequence Number | 047687 |
| HICL Sequence Number Description | MARIBAVIR |
| Brand/Generic | Brand |
| Proprietary Name | Livtencity |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | MARIBAVIR |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | TABLET, COATED |
| Route | ORAL |
| Active Ingredient Strength | 200 |
| Active Ingredient Units | mg/1 |
| Substance Name | MARIBAVIR |
| Labeler Name | Takeda Pharmaceuticals America, Inc. |
| Pharmaceutical Class | Breast Cancer Resistance Protein Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], Cytomegalovirus pUL97 Kinase Inhibitor [EPC], Cytomegalovirus pUL97 Kinase Inhibitors [MoA], P-Glycoprotein Inhibitors [MoA] |
| DEA Schedule | n/a |
| Marketing Category | NDA |
| Application Number | NDA215596 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 64764-0800-28 (64764080028)
| NDC Package Code | 64764-800-28 |
|---|---|
| Billing NDC | 64764080028 |
| Package | 1 BOTTLE in 1 CARTON (64764-800-28) / 28 TABLET, COATED in 1 BOTTLE |
| Marketing Start Date | 2021-11-23 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |